Oleg Nodelman has been our Chief Executive officer since our inception in April 2020 and is our Chairman Nominee. Mr. Nodelman has been the Portfolio Manager of EcoR1, a biotech-focused investment advisory firm that invests in companies at all stages of research and development, since he founded it in 2013. With nearly 20 years of experience in biotech investing, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was an analyst and portfolio manager from 2001 to 2012 at Biotechnology Value Fund. Prior to BVF, Mr. Nodelman worked in strategic consulting and organizational management at Mercer Management Consulting (now Oliver Wyman). He currently serves as a Board Member for Prothena (Nasdaq: PRTA), a clinical-stage neuroscience company focused on the discovery and development of novel therapies. Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University. Mr. Nodelman is well qualified to serve as the Chairperson of our board of directors because of his experience serving on the boards of directors of public and private companies in the pharmaceutical/biotechnology sector, as well as his role as Founder and Portfolio Manager of EcoR1.

Scott Perlen has been our Chief Financial Officer since our inception in April 2020. Mr. Perlen has been the Chief Financial Officer of EcoR1 since joining the firm in 2019. He oversees accounting and finance for EcoR1 and its investment funds as well as the funds’ day to day trade operations. Prior to joining EcoR1 in 2019, Mr. Perlen served as Chief Financial Officer for seven years at Sheffield Asset Management, LLC, a Chicago-based investment firm. Prior to Sheffield, Mr. Perlen was a Vice President at Grosvenor Capital Management, LP, a global leader in the alternative asset industry. During his seven years at Grosvenor, Mr. Perlen managed a group dedicated to providing outsourced CFO functionality to a number of investment firm managers and also assisted in performing operational due diligence reviews on underlying investment firms. Prior to joining Grosvenor in 2005, Mr. Perlen was an Assistant Vice President at Bank of America, focusing on operational risk and accounting for the bank’s derivatives business. From 1997 to 2002, Mr. Perlen managed the operations and fund accounting at Sunrise Capital Partners, LLC, a San Diego-based investment firm. Mr. Perlen received his Bachelor of Science in Finance from the University of Illinois at Urbana-Champaign in 1997.

Scott Platshon has been our Chief Operating Officer since our inception in April 2020. Mr. Platshon joined EcoR1 in 2015 where he currently serves as a Principal and is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. Mr. Platshon previously worked at Aquilo Partners, a boutique life sciences investment bank. Mr. Platshon holds a Bachelor of Science in Bioengineering from Stanford University.

Caroline Stout has been our Chief Investment Officer since our inception in April 2020. Ms. Stout joined EcoR1 in 2014 where she currently serves as a Principal. At EcoR1, she has led several of the firm’s investments in the biotechnology sector. Ms. Stout previously worked as an Investment Banking Analyst at Credit Suisse in New York. She has experience working on a range of transactions in the healthcare and biotechnology sectors, including leveraged buyouts, initial public offerings and follow-on equity raises. Ms. Stout graduated magna cum laude from Georgetown University with a Bachelor of Arts in Economics, a Pre-Medical concentration, and Cognitive Science minor.

Daniel Bradbury has agreed to serve on our board of directors following the completion of this offering. Since January 2020, Mr. Bradbury has served as Executive Chairman of Equillium, Inc. (Nasdaq: EQ), a biopharmaceutical company that develops products to treat severe autoimmune and inflammatory disorders with high unmet medical need and which he co-founded. Mr. Bradbury served as Chairman of Equillium, Inc. from March 2018 through December 2019. Mr. Bradbury also previously served as Chief Executive Officer of Equillium, Inc., from June 2018 through December 2019 and as President of Equillium, Inc. from March 2017 until June 2018. He has also served as the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm, since 2012. Prior to co-founding Equillium, he served as the President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes, and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012 for $7 billion. Before joining Amylin, Mr. Bradbury worked in marketing and sales for 10 years at SmithKline Beecham Pharmaceuticals. He serves on the board of directors of Intercept Pharmaceuticals (Nasdaq: ICPT), Castle Biosciences, Inc. (Nasdaq: CSTL), and a number of private companies and philanthropic organizations. Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. Mr. Bradbury is well qualified to serve on our board of directors because he has extensive experience in the biopharmaceutical industry, has demonstrated leadership and operational skills and possesses significant research, development and commercialization expertise, as well as public company board experience.

Graham Cooper has agreed to serve on our board of directors following the completion of this offering. Mr. Cooper is a member of the boards of directors of Unity Biotechnology (Nasdaq: UBX), Kezar Life Sciences (Nasdaq: KZR), Beam Therapeutics (Nasdaq: BEAM) and Applied Molecular Transport (private). Mr. Cooper also previously served as a member of the board of directors of Celladon Corporation, which merged with Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) in 2016. From March 2018 until May 2019, Mr. Cooper served as the Chief Financial Officer and Chief Operating Officer of Assembly Biosciences, Inc. Prior to joining Assembly, he was Chief Financial Officer of Receptos, Inc., from 2013 until its sale in 2015 to Celgene for $7.8 billion. In 2012, Mr. Cooper was the Chief Financial Officer of Geron Corporation, a biopharmaceutical company focused on cancer therapies. From 2006 until 2011, Mr. Cooper served as Chief Financial Officer of Orexigen Therapeutics, Inc., a biotechnology company focused on obesity therapies. From 1999 to 2006, Mr. Cooper held positions of increasing responsibility including Director, Health Care Investment Banking, at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From 1992 to 1995, he worked as an accountant at Deloitte & Touche, where he earned his C.P.A. Mr. Cooper holds a B.A. in Economics from the University of California at Berkeley and an M.B.A. from the Stanford Graduate School of Business. Mr. Cooper is well qualified to serve on our board of directors due to his significant financial and accounting experience in the life sciences industry.

Faheem Hasnain has agreed to serve on our board of directors following the completion of this offering. In 2015, Mr. Hasnain co-founded Gossamer Bio (Nasdaq: GOSS), a publicly traded biotechnology company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, and served as its Chief Executive Officer through July 2018, at which time he became Gossamer Bio’s Executive Chairman. Since 2019, Mr. Hasnain has served as non-executive Chairman of Gossamer Bio. Prior to Gossamer Bio, Mr. Hasnain served as President, Chief Executive Officer and a director of Receptos, Inc. from November 2010 until the company’s acquisition by Celgene Corporation in August 2015 for $7.8 billion. Prior to joining Receptos, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010 for over $700 million. Previously, Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc., a biotechnology company specializing in neurological disorders, autoimmune disorders and cancer, most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen Idec, Mr. Hasnain held roles at Bristol Myers Squibb, where he was President of the Oncology Therapeutics Network, and at GlaxoSmithKline and its predecessor organizations, the latter for 14 years. He has been Chairman of the Board of Sente, Inc. since 2008, Chairman of the Board of Tocagen Inc. (Nasdaq: TOCA) since November 2014, Lead Independent Director of Kura Oncology (Nasdaq: KURA) since 2015, Chairman of the Board of Mirati Therapeutics, Inc. (Nasdaq: MRTX) since February 2019 and a member of the Board of Overseers of Scripps Research Institute since 2018. He previously served as Chairman of the Board of Ambit Biosciences Corporation and served as a member of the Board of Directors of Tercica, Inc., Aragon Pharmaceuticals, Somaxon Pharmaceuticals, Inc. and Vital Therapies, Inc. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada. Mr. Hasnain is well qualified to serve on our board of directors because of his years of experience in drug discovery and development and as a biopharmaceutical executive and board member.

Sarah Marriott has served as our Secretary and on our board of directors since our inception in April 2020. Ms. Marriott joined EcoR1 in 2014 and is the firm’s Chief Operating Officer and Chief Compliance Officer, where she is responsible for operational, regulatory and compliance issues. Ms. Marriott has experience working across the diverse areas of civil and criminal litigation. Prior to EcoR1, she served as a Deputy District Attorney in Solano County, California. Prior to serving as a prosecutor, Ms. Marriott practiced at Orrick, Herrington & Sutcliffe LLP in San Francisco, where she handled commercial litigation matters. Ms. Marriott previously completed a clerkship on the federal Court of Appeals for the Tenth Circuit. Ms. Marriott holds a law degree from the University of California, Berkeley, and a Bachelor of Arts degree from Amherst College. Ms. Marriott is well qualified to serve on our board of directors due to her experience in the pharmaceutical/biotechnology sector, as well as her role as Chief Operating Officer and Chief Compliance Officer of EcoR1.

Shalini Sharp has agreed to serve on our board of directors following the completion of this offering. Ms. Sharp is currently the Chief Financial Officer at Ultragenyx (Nasdaq: RARE), which she joined in May 2012. She is responsible for leading the corporate finance, strategy, and information technology functions and is a member of the company’s executive leadership team. Ms. Sharp is a member of the Board of Directors of Neurocrine Biosciences (Nasdaq: NBIX), a neuroscience-focused biopharmaceutical company, Sutro Biopharma (Nasdaq: STRO), a drug discovery, development and manufacturing company focused on creating next-generation oncology therapeutics, and Precision Biosciences, a privately-held genome editing company. She is also a board member of TB Alliance, a non-profit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world. She previously served on the Board of Array Biopharma from 2017 until its sale to Pfizer in 2019. Prior to Ultragenyx, Ms. Sharp was Chief Financial Officer of Agenus Inc. (Nasdaq: AGEN), a biotechnology company focused on cancer immunotherapies from 2006 to 2012 and served on the Board of Agenus from 2012 to 2018. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development. Prior to Agenus, Ms. Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that company’s restructuring. Ms. Sharp was also a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices. Ms. Sharp holds both a B.A., magna cum laude, and M.B.A., from Harvard University. Ms. Sharp is well qualified to serve on our board of directors because of her 25 years in the life sciences industry, extensive experience as a chief financial officer of a public company, her financial acumen, and her management and leadership skills.